In comparison with the control, lower serum levels of IL-2 were seen in the LGG-, ECPJSmix-, Bb99-, and PJS-treated groups; KC in the LGG-, Bb99-, EcN-, and ECPJSmix-treated groups; IFNγ and IL-17 in the LGG- and ECPJSmix-treated groups; IL-10 in the Bb99- and ECPJSmix-treated groups; IL-6 in the LGG-treated group; and TNFα and IL-13 in the ECPJSmix-treated group. The gene discussed is IL17A; the disease is Peutz-Jeghers syndrome.